Restless Legs Syndrome - Pipeline Review, Q4 2010

Date: November 1, 2010
Pages: 38
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: RDC63F933ADEN
Leaflet:

Download PDF Leaflet

Restless Legs Syndrome - Pipeline Review, Q4 2010
Restless Legs Syndrome – Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Restless Legs Syndrome Pipeline Review, Q4 2010”, provides an overview of the Restless Legs Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Restless Legs Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome. “Restless Legs Syndrome-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Restless Legs Syndrome.
  • A review of the Restless Legs Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Restless Legs Syndrome pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Restless Legs Syndrome therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Restless Legs Syndrome
Restless Legs Syndrome Therapeutics under Development by Companies
Restless Legs Syndrome Therapeutics under Investigation by Universities/Institutes
Companies Involved in Restless Legs Syndrome Therapeutics Development
Kyowa Hakko Kirin Co., Ltd.
GlaxoSmithKline plc
Ligand Pharmaceuticals Incorporated
Jazz Pharmaceuticals, Inc.
axxonis Pharma AG
UCB S.A.
Universities/Institutes Involved in Restless Legs Syndrome Therapeutics Development
Restless Legs Syndrome Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Horizant - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Horizant - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lisuride TDS – RLS - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Rotigotine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Bupropion - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Restless Legs Syndrome - Featured News
Nov 05, 2010: GlaxoSmithKline And XenoPort Respond To FDA On Horizant For Restless Legs Syndrome
Jul 28, 2010: UCB Reports Clinical Study Results Of Neupro For Treatment Of Restless Legs Syndrome
Apr 15, 2010: EPO Rules European Patent For XP13512 Is Valid
Apr 15, 2010: EPO Rules European Patent For XP13512 Is Valid
Apr 15, 2010: Idera Announces Positive Phase I Data Of IMO-2125 In Null Responder HCV Patients At EASL 2010
Apr 13, 2010: UCB's Neupro Data Showed Sustained Five-year Benefit On Symptoms Of Restless Legs Syndrome
Feb 17, 2010: GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant(GSK1838262/XP13512) for RLS
Feb 11, 2010: XenoPort Announces Extension Of The Horizant PDUFA Date
Feb 04, 2010: XenoPort Announces Horizant As Brand Name For XP13512
Feb 04, 2010: XenoPort Announces Horizant as Brand Name for XP13512
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Restless Legs Syndrome, 2010
Products under Development for Restless Legs Syndrome – Comparative Analysis, 2010
Kyowa Hakko Kirin Co., Ltd., 2010
GlaxoSmithKline plc, 2010
Ligand Pharmaceuticals Incorporated, 2010
Jazz Pharmaceuticals, Inc., 2010
axxonis Pharma AG, 2010
UCB S.A., 2010
Assessment by Monotherapy Products, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010 23

LIST OF FIGURES

Number of Products under Development for Restless Legs Syndrome, 2010
Products under Development for Restless Legs Syndrome – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Assessment by Monotherapy Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 22
Restless Legs Syndrome - Pipeline Review, H2 2012 US$ 2,000.00 Sep, 2012 · 54 pages
Frozen Shoulder Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Sjogren's Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages

Ask Your Question

Restless Legs Syndrome - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: